Schering Corporation v. Sun Ray Drug Co., a Pennsylvania Corporation and Consolidated Sun Ray, Inc., a Delaware Corporation

320 F.2d 72, 1963 U.S. App. LEXIS 4689, 1963 Trade Cas. (CCH) 70,836
CourtCourt of Appeals for the Third Circuit
DecidedJuly 8, 1963
Docket14256_1
StatusPublished
Cited by11 cases

This text of 320 F.2d 72 (Schering Corporation v. Sun Ray Drug Co., a Pennsylvania Corporation and Consolidated Sun Ray, Inc., a Delaware Corporation) is published on Counsel Stack Legal Research, covering Court of Appeals for the Third Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Schering Corporation v. Sun Ray Drug Co., a Pennsylvania Corporation and Consolidated Sun Ray, Inc., a Delaware Corporation, 320 F.2d 72, 1963 U.S. App. LEXIS 4689, 1963 Trade Cas. (CCH) 70,836 (3d Cir. 1963).

Opinion

KALODNER, Circuit Judge.

This appeal from the District Court’s Order granting a preliminary injunction restraining defendant from selling Coricidin, plaintiff’s trademarked product, below its fair trade price, in unfair competition as that term is defined in the Pennsylvania Fair Trade Act, 1 presents two issues:

(1) Did the District Court err in finding that the requisite jurisdictional amount of $10,000 has been established?
(2) Did the District Court abuse its discretion in granting a preliminary injunction?

The following findings of fact were made by the District Court following hearings had on plaintiff’s prayer for a preliminary injunction

1. Plaintiff is a New Jersey corporation with its principal office and' place of business in Bloomfield, New Jersey. It is not registered to do-business in Pennsylvania.
2. Defendant, Sun Ray Drug Co., 2 is a Pennsylvania corporation with its principal office and place-of business in Philadelphia, Pennsylvania, operating one hundred and fifty stores.
3. Plaintiff is, and has been since at least 1935, engaged in the business of manufacturing and selling drugs, medicines, pharmaceuticals and ethical products.
*74 4. Plaintiff has expended large sums of money in promoting and advertising its products under its name and registered trademarks and has established a valuable reputation and good will for such products and the trademarks under which they are produced and sold.
5. Plaintiff’s advertising program consists of advertising in trade journals which are circulated among pharmacies and other retailers of its products, among wholesalers of its products and among hospitals and physicians. It also consists of providing pharmacies with point-of-sale displays of its products and efforts on the part of its detail men (who are salesmen) to promote the sale and use of its products through physicians, pharmacies and the like. It has also engaged, and is presently engaging, in an advertising and promotional campaign on television in a test market served by an Indiana television station. The amounts expended nationally by the plaintiff in its advertising and promotional campaigns have been at the rate of approximately $5,000,000 annually for the five full years ending with the year 1961, and its national advertising and promotional expense during the year 1962 is running at approximately the same rate. The plaintiff’s expenditures for advertising and promoting its “Coricidin” line of products during the same periods have been at the annual rate of approximately $750,000.
6. The annual rate of the plaintiff’s gross sales of its products, all of which are identified by its name and trademarks, is approximately $80,000,000 of which approximately $40,000,000 represents domestic gross sales in the United States and approximately $10,000,000 represents domestic gross sales of the plaintiff’s “Coricidin” products.
7. The value of the plaintiff’s good will is substantial and the amount in controversy in this action is in excess of $10,000.
8. The sale of the plaintiff’s products bearing the plaintiff’s trademarks below their established fair trade prices will materially and adversely affect plaintiff’s good will.
9. The plaintiff is the owner of three registered trademarks which are material in this case, namely, the name “Schering” (U. S. Trademark Registration No. 588,824), the name “Schering” combined with representations of a flask and a crucible (Registration No. 324,677) and the word “Coricidin” (U. S. Trademark Registration No. 533,777) all of which are currently in use by the plaintiff.
10. Plaintiff’s trademarks are affixed to and displayed on the containers in which the plaintiff’s products are packaged and, when possible, on the products themselves.
11. Pursuant to the Pennsylvania Fair Trade Act, Act of June 5, 1935, P.L. 266, as amended 73 P.S. Sections 7-11, plaintiff has entered into approximately eighty agreements with retail dealers in the Greater Philadelphia marketing area in Pennsylvania under which plaintiff established minimum retail prices for its over-the-counter products, including the various products sold by it under the Coricidin trademark.
12. The products manufactured by the plaintiff and bearing the trademarks owned and used by the plaintiff are in fair and open competition with commodities of the same general class manufactured, produced and sold by others.
13. On or about December 14, 1961 plaintiff notified the defendant at its principal office at 8000 Penrose Avenue, Philadelphia, Pennsylvania, of plaintiff’s minimum retail prices for its over-the-counter products which it had established under the provisions of the Pennsylvania Fair Trade Act.
*75 14. Since December 14, 1961 defendant has been selling “Coricidin” products of the plaintiff at less than the minimum retail prices fixed therefor by the plaintiff. The aforesaid notice with which was enclosed a copy of one of the plaintiff’s fair trade contracts and a copy of its current fair trade price list was duly delivered to the defendant.
15. There is no evidence that the defendant’s sale of the plaintiff’s products at retail at prices less than those stipulated in plaintiff’s contracts with retailers under the Pennsylvania Fair Trade Act were for the purpose of closing out defendant’s stock of such products for the purpose of discontinuing delivery thereof or were sales of perishable or deteriorating goods or were sales made by an officer acting under the orders of any court.
The District Court stated its Conclusions of Law as follows:
1. This Court has jurisdiction over the parties to and the subject matter of this action.
2. Defendant has wilfully and knowingly offered for sale and sold “Coricidin” products in violation of the provision of the Pennsylvania Fair Trade Act.
3. The aforesaid actions of the defendant constitute unfair competition under the Pennsylvania Fair Trade Act.
4. The continued violation by the defendant of the Pennsylvania Fair Trade Act threatens irreparable injury to the plaintiff’s good will in its “Coricidin” products.
5. Plaintiff is entitled to a preliminary injunction.

Defendant here challenges only two of the District Court’s determinations: (1) that “the amount in controversy in this action is in excess of $10,000” and (2) that the defendant’s sales of Coricidin at less than established fair trade price “threatens irreparable injury to the plaintiff’s good will in its ‘Coricidin’ products”.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
320 F.2d 72, 1963 U.S. App. LEXIS 4689, 1963 Trade Cas. (CCH) 70,836, Counsel Stack Legal Research, https://law.counselstack.com/opinion/schering-corporation-v-sun-ray-drug-co-a-pennsylvania-corporation-and-ca3-1963.